Uttar Pradesh News Desk

Dravet Syndrome Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Dravet Syndrome Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

July 02
18:32 2021
Dravet Syndrome Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

DelveInsight Business Research LLP
DelveInsight’s, “Dravet Syndrome – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Dravet Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight’s Dravet Syndrome Pipeline Insight report provides comprehensive insights about key companies and pipeline drugs in the Dravet Syndrome pipeline landscapes. It comprises Dravet Syndrome pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Dravet Syndrome therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Dravet Syndrome pipeline products.     

Some of the key takeaways of the Dravet Syndrome Pipeline Report  

  • Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Biocodex and GW Pharmaceuticals, etc., are developing therapies for the treatment of Dravet Syndrome.

  • Emerging therapies such as Diacomit and Epidiolex, are expected to have a significant impact on the  Dravet Syndrome market in the coming years.

  • OV935 (TAK-935), being co-developed by Ovid Therapeutics, Takeda is a first-in-class, highly selective inhibitor of the enzyme cholesterol 24 hydroxylase. Currently, the company is conducting Phase II trials after completing four Phase I trials in healthy volunteers.

Get an overview of pipeline landscape @ Dravet Syndrome Clinical Trials Analysis 

A dravet syndrome is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems.

Dravet Syndrome Emerging Drugs

  • Epidiolex by GW Pharmaceuticals

  • And others.

Scope of Dravet Syndrome Pipeline Drug Insight   

  • Coverage: Global 

  • Major Players: Biocodex, GW Pharmaceuticals, and others.

  • Pipeline Therapies: Diacomit, Epidiolex, and others.

Table of Contents

1

Dravet Syndrome Report Introduction

2

Dravet Syndrome Executive Summary

3

Dravet Syndrome Overview

4

Dravet Syndrome- Analytical Perspective In-depth Commercial Assessment

5

Dravet Syndrome Pipeline Therapeutics

6

Dravet Syndrome Late Stage Products (Phase II/III)

7

Dravet Syndrome Mid Stage Products (Phase II)

8

Dravet Syndrome Early Stage Products (Phase I)

9

Dravet Syndrome Preclinical Stage Products

10

Dravet Syndrome Therapeutics Assessment

11

Dravet Syndrome Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Dravet Syndrome Key Companies

14

Dravet Syndrome Key Products

15

Dravet Syndrome Unmet Needs

16 

Dravet Syndrome Market Drivers and Barriers

17

Dravet Syndrome Future Perspectives and Conclusion

18

Dravet Syndrome Analyst Views

19

Appendix

20

About DelveInsight

Related Reports:

Dravet Syndrome Market 

DelveInsight’s Dravet Syndrome – Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Dravet Syndrome, historical and forecasted epidemiology as well as the Dravet Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Dravet Syndrome Epidemiology

DelveInsight’s Dravet Syndrome – Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Dravet Syndrome epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/

Related Articles